We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Pfizer Inc. (NYSE:PFE) is one of the ...

Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large cap stocks ...

Pfizer beats Q2 estimates with $14.7B revenue and $0.78 EPS. Management showed extreme confidence by raising full-year EPS ...

Pfizer (PFE) stock slips as a Phase 3 trial failure for its sickle cell disease therapy inclacumab marks the latest setback ...

Pfizer (PFE) recently announced positive topline results from the Phase 3 EV-303 clinical trial, showcasing promising ...

Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on other drugs planned.

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the ...

In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal ...

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern ...

Drugmaker Pfizer ($PFE) recently shared disappointing news about its experimental drug for sickle cell disease, inclacumab. In a late-stage ...

One of the most appealing features of Pfizer's stock is its dividend. The payout recently yielded a hefty 7.4% -- and it's ...